Evidence map›Paper›PMID 30463996›Full record

Trial reportCancer discovery2019

Francisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, Geoffrey Y Ku, Yaelle Tuvy, Helen Won, Christopher J Fong, Nancy Bouvier, Gouri J Nanjangud, Joanne Soong and 29 more

Open access · greenAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 1 pooled it
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. The impact of the PI3K/AKT/mTOR signaling pathway on trastuzumab resistance in HER2-positive gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. The MET Oncogene Network of Interacting Cell Surface Proteins.International journal of molecular sciences · 2024
    Review
  20. [Molecular pharmaceutics · 2024
    Article

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

39 authors at 3 institutions in 1 country.

Francisco Sanchez-VegaMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jaclyn F HechtmanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Pau CastelHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Geoffrey Y KuDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.ORCID 0000-0002-0448-1038
Yaelle TuvyDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Helen WonMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Christopher J FongMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Nancy BouvierMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Gouri J NanjangudMolecular Cytogenetics Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
Joanne SoongDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Efsevia VakianiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Mark SchattnerDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
David P KelsenDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Robert A LefkowitzDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Karen BrownDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Mario E LacoutureDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Marinela CapanuDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Marissa MattarAntitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Besnik QeriqiAntitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Fabiola CecchiNantOmics, Rockville, Maryland.
Yuan TianNantOmics, Rockville, Maryland.
Todd HembroughNantOmics, Rockville, Maryland.
Rebecca J NagyGuardant Health, Inc., Redwood City, California.
Richard B LanmanGuardant Health, Inc., Redwood City, California.ORCID 0000-0001-8122-4329
Steven M LarsonDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Neeta Pandit-TaskarDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Heiko SchöderDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Christine A Iacobuzio-DonahueDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-4672-3023
David H IlsonDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
Wolfgang A WeberDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Michael F BergerMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Elisa de StanchinaAntitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Barry S TaylorMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jason S LewisDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-7065-4534
David B SolitMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jorge A Carrasquillo *Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Maurizio Scaltriti *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Nikolaus Schultz *Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Yelena Y Janjigian *Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York. janjigiy@mskcc.org.
Memorial Sloan Kettering Cancer Center · USUniversity of Maryland Rehabilitation & Orthopaedic Institute · USGuardant (United States) · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
MSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9M
Development of BRCA1-mimetic drugs for breast cancerR01CA150646 · NCI · GEORGETOWN UNIVERSITY · PI ROSEN, ELIOT M. · 2010 to 2014
$2.8M
Understanding Long Tail Driver Mutations in CancerR01CA204749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCHULTZ, NIKOLAUS · 2017 to 2021
$2.0M
NCI NIH HHS L30 CA162361NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA150646NCI NIH HHS R01 CA204749NIH HHS U54 OD020355
6 · The paper itself

Abstract

The anti-HER2 antibody trastuzumab is standard care for advanced esophagogastric (EG) cancer with

Indexed as

Gene AmplificationAfatinibAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesErbB ReceptorsEsophageal NeoplasmsEsophagogastric JunctionFollow-Up StudiesGene Expression Regulation, NeoplasticHumansPrognosisProto-Oncogene Proteins c-metStomach NeoplasmsTrastuzumabAfatinibBiomarkers, TumorEGFR protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesErbB ReceptorsMET protein, humanProto-Oncogene Proteins c-metTrastuzumab

Identifiers

PMID30463996
PMCPMC6368868
OpenAlexW2901467300

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.